- Hong Kong small-cap stocks showed a divergent trend recently, driven by regulatory changes and strategic adjustments.
- Biotech firms like JW Cayman Therapeutics saw a 15.4 % weekly gain after entering national medical insurance negotiations, while tech companies experienced mixed performances.
- This market fluctuation reflects small-cap enterprises' adaptive restructuring amid shifting regulatory environments and broader economic uncertainties.